PODD · Full Picture

INSULET CORP — the full picture

Earnings window · 2026-07-15 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Guidance and Outlook · Guidance & outlookPriority 86
    +19.8% revenue; 2 sources (news, press_release); 14 forward row(s); quote_verified
    Insulet lowered its full-year GAAP revenue growth guidance to 21%-23%.
  2. Revenue Performance and Mix · Revenue growth & mixPriority 83
    +136.1% revenue (realized); 3 sources (news, press_release, sec_filing); 1 forward row(s); structured_verified
    Net income was $95.0 million and $22.5 million for the three months ended June 30, 2026 and 2025, respectively.
  3. Gross Margin Drivers · Gross marginPriority 80
    -19.6% operating_income (realized); 2 sources (press_release, sec_filing); structured_verified
    Cost of revenue for the three months ended June 30, 2026 increased $42.3 million, or 21.5%, to $239.1 million, compared with $196.9 million for the three months ended June 30, 2025.
  4. International Omnipod Revenue Growth · Revenue growth & mixPriority 76
    +27.8% revenue (realized); 1 forward row(s); structured_verified
    Revenue from the sale of Omnipod products in our international markets increased $156.5 million, or 46.3%, to $494.6 million for the six months ended June 30, 2026, compared with $338.1 million for the six months ended June 30, 2025.
  5. Share Repurchase Program · Buybacks & dividendsPriority 76
    -9.4% cash; 1 forward row(s); structured_verified
    In February 2026, the Board of Directors extended our $125 million share repurchase program to December 31, 2027 and approved an additional $350 million in repurchases of common stock.
  6. Liquidity and Debt Position · Debt, leverage & refinancingPriority 74
    -13.1% cash (realized); structured_verified
    Net cash used in financing activities was $315.9 million for the six months ended June 30, 2026, compared with net cash used in financing activities of $65.8 million for the six months ended June 30, 2025.
  7. Product Safety Corrections · UnclassifiedPriority 71
    -4.0% operating_income; 1 forward row(s); structured_verified
    The Company estimates the MDCs and related costs will be in the range of $60 million to $70 million, most of which it expects to incur in 2026, with the remainder expected to be incurred in 2027.
  8. Net Income and Profitability · Operating income & profitabilityPriority 70
    +12.9% net_income (realized); 2 sources (news, press_release); quote_verified
    Net income for the quarter: $95.0 million, or $1.37 per diluted share, compared to $22.5 million, or $0.32 per diluted share, in the prior year quarter.
  9. Free Cash Flow and Capex · Capital expenditurePriority 64
    +16.5% operating_income (realized); quote_verified
    Free cash flow for the six months ended June 30, 2026: $145.4 million (net cash provided by operating activities $202.2 million less capital expenditures $56.8 million).
  10. FX / Currency Impact · Currency / FXPriority 61
    quote_verified
    Constant currency revenue growth for the three and six months ended June 30, 2026 was 22.7% and 26.2%, respectively; currency impact was 0.8% and 2.2%, respectively.
  11. Research and Development Expense · R&D investmentPriority 61
    -7.4% operating_income (realized); quote_verified
    Research and development expenses for the six months ended June 30, 2026 increased $44.8 million, or 33.7%, to $177.8 million, compared with $133.0 million for the six months ended June 30, 2025.
  12. End-Market Demand Trends · Demand, orders & backlogPriority 60
    2 sources (press_release, sec_filing); quote_verified
    The Company stated its financial objective is to sustain profitable growth and to achieve this continues to roll out Omnipod 5 in additional countries.

Threads by pillar

Revenue & Demand Priority 94 · 9 threads

Costs & Margins Priority 90 · 7 threads

Capital & Balance Sheet Priority 93 · 8 threads

Strategy & Portfolio Priority 53 · 1 thread

Legal, Regulatory & Policy Priority 71 · 5 threads

Guidance & Outlook Priority 86 · 1 thread

Macro & Market Conditions Priority 69 · 3 threads

Unclassified Priority 86 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
revenue+19.8%+19.8%+169.5%
cash-9.4%+9.4%-32.0%
operating_income-4.0%+4.0%-48.1%
liability-2.1%+2.1%-1.6%
margin+0.8%+0.8%—
assets——-2.9%
net_income——+36.5%